focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.60
Ask: 1.80
Change: -0.10 (-5.88%)
Spread: 0.20 (12.50%)
Open: 1.70
High: 1.60
Low: 1.60
Prev. Close: 1.70
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

30 Aug 2022 14:37

RNS Number : 6290X
Kanabo Group PLC
30 August 2022
 

Kanabo Group Plc

("Kanabo" or the "Company")

Grant of Options

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers, announces the grant of two types of options over a total of 22,759,150 shares to certain employees, pursuant to their terms of employment.

 

options

 

Name

No. of Options

Vested options as of today

Option Exercise Price

Vesting Period for non-vested options

Gil Efron )PDMR)

 

900,000

-

6.5p

 

 

Options shall vest over a 3-year period. 33% vest at the end of the 12-month period following the Vesting Start Date. The remaining options vest over 8 equal 3-month periods thereafter

 

900,000

-

8.0p

Daniel Poulter (PDMR)

900,000

600,000

6.5p

 

 

Options shall vest over a 3-year period. 33% vest at the end of the 12-month period following the Vesting Start Date. The remaining options vest over 8 equal 3-month periods thereafter

 

900,000

-

8.0p

Other Employees

6,927,200

-

8.0p

Options shall vest over a 3-year period. 33% vest at the end of the 12-month period following the Vesting Start Date. The remaining options vest over 8 equal 3-month periods thereafter

Other Employees

6,927,200

2,000,000

6.5p

Options shall vest over a 3-year period. 33% vest at the end of the 12-month period following the Vesting Start Date. The remaining options vest over 8 equal 3-month periods thereafter.

Other Employees*

975,527

162,588

10.15p

Options shall vest in 3 years on a quarterly basis

Other Employees*

2,437,628

406,271

12.65p

Options shall vest in 3 years on a quarterly basis

* These options replace options GP's employees had in GP. The options will only be exercisable in three years from date of acquisition and will be valid for 2 years from that date.

 

 

 

Options issued for past due debts

 

As part of the acquisition of The GP Service, the Company offset part of GP's payroll obligations for its various employees, from the overall consideration. The Company now reached an agreement with the employees to issue options in the Company in lieu of owed salaries.

 

The agreement states that in lieu of the £192,000 owed as salaries, the company will issue 1,891,595 options with an exercise price being at par. The number of options granted was calculated according to the transaction price of 12.65 pence less the company's nominal share value. The options will only be exercisable in two years from the date of issue [three years from date of acquisition] and will be valid for 3 years from that date.

 

 

 

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc

Avihu Tamir, CEO

Via Vox Markets

Peterhouse Capital Ltd

Eran Zucker / Lauren Riley

Tel: +44 (0)20 7469 0930

Vox Markets (Investor Relations)

Kat Perez

KanaboGroup@voxmarkets.co.uk

 

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Gil Efron

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

6.5p

900,000

8.0p

900,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

21.3.2022

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Daniel Poulter

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

6.5p

900,000

8.0p

900,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.7.2021

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBKKBNNBKDDFN
Date   Source Headline
2nd Dec 20222:59 pmRNSResignation of Auditor
15th Nov 20227:30 amRNSUpdate re: Investment into Hellenic Dynamics
24th Oct 20227:00 amRNSKanabo appointed to BSI Steering Group Committee
30th Sep 20227:01 amRNSInvestor Webinar hosted by Vox Markets
30th Sep 20227:00 amRNSHalf-year Report
30th Aug 20222:37 pmRNSGrant of Options
19th Aug 20225:30 pmRNSAppointment of Auditor
17th Aug 20222:05 pmRNSSecond Price Monitoring Extn
17th Aug 20222:00 pmRNSPrice Monitoring Extension
3rd Aug 20229:05 amRNSSecond Price Monitoring Extn
3rd Aug 20229:00 amRNSPrice Monitoring Extension
30th Jun 20225:02 pmRNSResult of AGM
30th Jun 20223:29 pmRNSAGM Statement
16th Jun 20227:00 amRNSNew Subsidiary
9th Jun 20227:00 amRNSContract Extension
8th Jun 20221:00 pmRNSNotice of AGM
6th Jun 20227:00 amRNSFinal Results
20th May 20227:00 amRNSUpdate on the Acquisition of Materia
3rd May 20227:00 amRNSTotal Voting Rights
19th Apr 20223:00 pmRNSExercise of Options and Total Voting Rights
22nd Mar 20227:00 amRNSBoard Changes
11th Mar 202211:23 amRNSInvestor Updates
9th Mar 20227:00 amRNSMoU with Forbe Ltd
1st Mar 20222:05 pmRNSSecond Price Monitoring Extn
1st Mar 20222:00 pmRNSPrice Monitoring Extension
28th Feb 20222:00 pmRNSTotal Voting Rights
25th Feb 20227:00 amRNSDirector/PDMR Dealing
23rd Feb 20227:00 amRNSBlock listing Interim Review
22nd Feb 20229:05 amRNSSecond Price Monitoring Extn
22nd Feb 20229:00 amRNSPrice Monitoring Extension
22nd Feb 20227:00 amRNSCompany Webinar
21st Feb 20225:30 pmRNSExercise of Put Option
21st Feb 20225:15 pmRNSOversubscribed Placing to Raise £2.25m
21st Feb 20224:54 pmRNSAcquisition of GP Service Ltd
31st Jan 202211:00 amRNSTotal Voting Rights
18th Jan 20227:00 amRNSMateria Announces Trading Update for 4Q22
6th Jan 20224:41 pmRNSSecond Price Monitoring Extn
6th Jan 20224:36 pmRNSPrice Monitoring Extension
31st Dec 202111:41 amRNSTotal Voting Rights
31st Dec 202110:00 amRNSGrant of Options
30th Dec 20211:00 pmRNSAchievement of Milestones
16th Dec 20217:05 amRNSMateria Malta First Sales in Europe
15th Dec 20217:00 amRNSPatent Advancement
7th Dec 20217:00 amRNSSubmission for Bioavailability and Efficacy Trial
6th Dec 20213:45 pmRNSExercise of Options
6th Dec 20217:00 amRNSUK Moves to License e-cigarettes and vaporizers
30th Nov 20214:02 pmRNSTotal Voting Rights
29th Nov 202111:05 amRNSSecond Price Monitoring Extn
29th Nov 202111:00 amRNSPrice Monitoring Extension
26th Nov 202111:57 amRNSKanabo to present at Mello: 29 November 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.